Increasing use of contralateral prophylactic mastectomy: A counterintuitive trend

ONCOLOGY

Volumn 22, Issue 5, 2008, Pages 548-551

  Wood, William C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ARTICLE; BREAST AREOLA; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CONTRALATERAL PROPHYLACTIC MASTECTOMY; DOCTOR PATIENT RELATION; FAMILY HISTORY; GENE MUTATION; HEALTH BELIEF; HUMAN; INVASIVE CARCINOMA; LUNG CARCINOMA; MASTECTOMY; MEDICAL ETHICS; ONSET AGE; OVARIECTOMY; RISK BENEFIT ANALYSIS; SEXUAL AROUSAL; TUMOR SUPPRESSOR GENE; BREAST TUMOR; FEMALE; GENETICS; MUTATION; NOTE; PATHOLOGY; RISK ASSESSMENT;

BREAST NEOPLASMS; ETHICS, MEDICAL; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MASTECTOMY; MUTATION; RISK ASSESSMENT;

EID: 50949106774     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Tuttle TM, Habermann EB, Grund EH, et al: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 25: 1-7, 2007.
2. Montgomery LL, Tran KN, Heelan MC, et al: Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6:546-552, 1999.
3. Hemminki K, Jianguang J, Försti A: Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67:868-870, 2007.
4. Vo TN, Meric-Bernstam F, Yi M, et al: Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192:552-555, 2006.
5. Lee JSY, Grant CS, Donahue JH, et al: Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118:640,648, 1995.
6. Peiro G, Bornstein BA, Connolly IL, et al: The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 59:49-54, 2000.
7. Chung MA, Cole B, Wanebo HJ, et al: Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 4:545-550, 1997.
8. Yeatman TJ, Lyman GH, Smith SK, et al: Bilaterality and recurrence rates for lobular breast cancer: Considerations or treatment. Ann Surg Oncol 4:198-202; 1997.
9. Bertelsen L, Bernstein L, Olsen JH, et al: Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32-40, 2008.
10. Tercyak KP, Peshkin BN, Brogan BM, et al: Quality of life after contratateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 testing. J Clin Oncol 25:285-291, 2007.
11. Bostwick J 3rd, Wood WC: Contralateral prophylactic mastectomies (editorial). Ann Surg Oncol 6:519, 1999.